AbbVie stock holds near highs as new lung cancer data and Q2 2026 growth reshape the outlook
Published on 08/22/2026 at 13:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. (US00287Y1091) stock is trading close to its recent high as investors weigh strong Q2 2026 growth, raised full-year guidance, and new lung cancer data presented at the 2026 World Conference on Lung Cancer as of August 21, 2026.
Recent market data show AbbVie shares opening at $265.62 on the latest trading session, a level that sits above a last reported close of $261.07, underscoring modest recent gains and a year-to-date advance of 14.26% as of early July 2026. Per consensus figures compiled in current coverage, the stock carries a rating of Moderate Buy and an average price target of $275.95, leaving a gap of more than $10 between the latest open and the targeted level.
For investors, the combination of near-peak trading levels, double-digit revenue growth, and an expanding oncology pipeline makes the AbbVie story more about execution on new therapies than the lingering Humira patent cliff.
Q2 2026 results highlight the Skyrizi and Rinvoq growth engine
According to a recent pharmaceutical industry overview on Q2 2026 performance, AbbVie’s net revenue for Q2 2026 rose 10.2% to $17.0 billion, reflecting broad-based growth across its immunology and oncology portfolios for the quarter ended in June 2026. This double-digit increase provides a concrete sign that the company is returning to growth even as Humira faces ongoing biosimilar competition in major markets.
The same Q2 2026 review indicates that Skyrizi generated revenue of $5.5 billion in the quarter, while Rinvoq contributed $2.5 billion, with both products delivering year-over-year growth rates of 24.0% and 23.7%, respectively. Together, these two immunology drugs produced $8.03 billion in sales during Q2 2026, more than 10 times the $756 million recorded by Humira, whose revenue declined 36.1% from the prior-year period.
This numerical shift illustrates how quickly AbbVie has diversified away from its legacy blockbuster. Historically, Humira dominated AbbVie’s sales mix, but in Q2 2026 Skyrizi and Rinvoq together generated over ten times Humira’s revenue, signaling a decisive transition toward newer therapies that can sustain long-term growth beyond the patent cliff era.
Management used the Q2 2026 momentum to raise full-year guidance, lifting projected 2026 net revenue to $67.6 billion. The higher outlook reflects confidence that immunology demand and new indications can carry the business, even as older molecules mature and competitive pressures intensify.
Guidance, valuation and consensus view around AbbVie stock
The updated full-year 2026 revenue guidance of $67.6 billion represents a step up from prior expectations and underpins the supportive consensus view on AbbVie stock. With Q2 2026 net revenue at $17.0 billion, the implied run-rate suggests that management expects continued solid performance in the back half of the year, helped by expanding use of Skyrizi and Rinvoq and incremental contributions from newer oncology assets.
Recent coverage summarizing market data shows AbbVie shares opening at $265.62 on the most recent trading day, while a market quote snapshot lists a last close at $261.07 with a 3.99% single-day gain and a year-to-date performance of 14.26% as of July 2, 2026. At these levels, AbbVie trades below the average analyst price target of $275.95, placing the stock more than 4% under the consensus fair value implied by current models.
The spread between the $265.62 open and the $275.95 target highlights that analysts see room for further upside if the company can deliver on its raised guidance and pipeline milestones. In addition, various portfolio filings reported in current data show institutional investors maintaining and adjusting sizable positions in AbbVie, reinforcing the view that the stock remains a core holding for many long-horizon strategies focused on pharma and biotech income and growth.
For valuation-focused investors, the key question is whether the strong immunology growth and improving oncology traction can sustain mid-single- to low-double-digit top-line expansion beyond 2026, thereby supporting current price levels and the consensus target.
New lung cancer data at WCLC 2026 supports the oncology pipeline
Beyond immunology, AbbVie has been emphasizing its oncology pipeline, and new lung cancer data presented at the 2026 World Conference on Lung Cancer (WCLC 2026) provide important context. According to a company announcement reported in current healthcare coverage, AbbVie showcased new clinical data across multiple lung cancer programs, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
One detailed report on the WCLC 2026 presentations notes that AbbVie unveiled efficacy and safety updates for investigational therapies such as ABBV-1480, telisotuzumab adizutecan, and ABBV-706. These molecules are being evaluated across various lung cancer settings, with the clinical data focused on response rates, durability, and tolerability in both NSCLC and SCLC populations.
The same WCLC 2026 overview explains that AbbVie is pursuing an expanded set of lung cancer trials, positioning these programs as a potential contributor to the company’s future oncology portfolio and longer-term growth profile. The company emphasized that telisotuzumab adizutecan and ABBV-706 remain investigational and are not approved by any health authorities worldwide, underscoring that the lung cancer work is still in the development stage rather than a current commercial driver.
In the broader pipeline context, AbbVie has also announced plans for a $10.9 billion acquisition of Apogee Therapeutics to extend its immunology portfolio into dermatology and respiratory disease. When combined with the lung cancer programs, these moves suggest a strategy focused on deepening the company’s presence in immune-mediated and oncology conditions with high unmet need.
For investors tracking catalysts, the WCLC 2026 data serve as a forward-looking narrative element: while they do not immediately translate into revenue, they help frame potential future indications and market segments that could complement Skyrizi and Rinvoq as growth drivers later in the decade.
Immunology and oncology products underpin AbbVie’s strategy
Skyrizi, a monoclonal antibody targeting IL-23, and Rinvoq, a JAK inhibitor, have become the cornerstone of AbbVie’s post-Humira immunology strategy. In Q2 2026, their combined $8.03 billion in revenue and growth rates above 20% demonstrate how effectively the company has positioned these drugs across psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and other immune-mediated conditions.
The Q2 2026 figures show that Skyrizi alone generated $5.5 billion in quarterly revenue, reflecting broad adoption and increasing penetration in existing indications. Rinvoq’s $2.5 billion in revenue, paired with its 23.7% year-over-year growth, signals that AbbVie is successfully leveraging the drug’s label expansion strategy, adding new autoimmune indications over time.
On the oncology side, the investigational lung cancer agents highlighted at WCLC 2026 complement AbbVie’s existing hematology and oncology portfolio. ABBV-1480, telisotuzumab adizutecan, and ABBV-706 are being studied in diverse lung cancer cohorts, and the latest data presentations underscore the company’s commitment to building a multi-asset pipeline that could one day rival its immunology franchise in scale.
Historically, Humira’s $756 million in Q2 2026 revenue, down 36.1% from the prior-year quarter, reminds investors that legacy product decline remains part of the AbbVie story. Yet the magnitude of the Skyrizi and Rinvoq contribution compared with Humira illustrates that the company has already passed an important inflection point in repositioning its portfolio.
Product spotlight: Skyrizi as a representative AbbVie therapy
Skyrizi serves as a representative product for understanding AbbVie’s current trajectory. Approved for multiple inflammatory indications, Skyrizi is administered as a subcutaneous injection and targets IL-23, a cytokine involved in autoimmune disease pathways. The drug has become widely used in plaque psoriasis, often competing with other biologics that also target IL-23 or related cytokines.
In Q2 2026, Skyrizi’s $5.5 billion in revenue underscores its position as one of the largest single products in AbbVie’s lineup. The 24.0% year-over-year growth rate from Q2 2025 to Q2 2026 indicates that the company is still expanding the drug’s reach, both by gaining share in existing indications and by adding new label approvals and geographies.
For patients, Skyrizi’s clinical data have highlighted durable skin clearance and symptom relief, while for AbbVie, the drug offers a long-dated patent runway that can support sustainable cash flows. As more real-world data accumulate and physicians gain experience with the therapy, AbbVie is likely to continue emphasizing Skyrizi’s role in differentiated outcomes, especially in difficult-to-treat patient subsets.
AbbVie stock and recent trading levels
AbbVie shares trade on the New York Stock Exchange under the ticker ABBV. Recent quote snapshots show the stock opening at $265.62 on the latest trading session referenced in current market coverage. A prior close of $261.07 as of July 2, 2026, was associated with a single-day gain of 3.99% and a year-to-date advance of 14.26% at that point, indicating solid performance for the stock during 2026.
The gap between the $265.62 open and the average price target of $275.95 highlights that current trading levels remain below the consensus fair value derived from recent analyst models. For investors, this spread suggests that if AbbVie can continue delivering double-digit top-line growth, progress on lung cancer trials, and successful integration of planned acquisitions such as Apogee Therapeutics, the stock may have scope to trend closer to the consensus target.
Read more
More on AbbVie stock can be found in the latest company materials available through the AbbVie website.
Company fact box
Company: AbbVie Inc.
ISIN: US00287Y1091
Ticker: ABBV
Exchange: New York Stock Exchange
Sector / Industry: Pharmaceuticals / Biotechnology
Index membership: S&P 500
